MCID: CHR066
MIFTS: 61

Chronic Fatigue Syndrome

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 12 50 52 41 3 14 69
Myalgic Encephalomyelitis 12 50
Chronic Fatigue Immune Dysfunction Syndrome 50
Systemic Exertion Intolerance Disease 50
Postviral Fatigue Syndrome 12
Fatigue Syndrome, Chronic 42
Myalgic Encephalitis 12
Cfs 12

Classifications:



Summaries for Chronic Fatigue Syndrome

MedlinePlus : 41 chronic fatigue syndrome (cfs) is a disorder that causes extreme fatigue. this fatigue is not the kind of tired feeling that goes away after you rest. instead, it lasts a long time and limits your ability to do ordinary daily activities. the main symptom of cfs is severe fatigue that lasts for 6 months or more. you also have at least four of these other symptoms: feeling unwell for more than 24 hours after physical activity muscle pain memory problems headaches pain in multiple joints sleep problems sore throat tender lymph nodes cfs is hard to diagnose. there are no tests for it, and other illnesses can cause similar symptoms. your doctor has to rule out other diseases before making a diagnosis of cfs. no one knows what causes cfs. it is most common in women in their 40s and 50s, but anyone can have it. it can last for years. there is no cure for cfs, so the goal of treatment is to improve symptoms. cfs affects people in different ways. you should work with your doctors to create a treatment program that best meets your own needs. it may include therapies to manage your symptoms, such as medicines to treat pain, sleep disorders, and other problems. it may also include coping techniques, and ways of managing your daily activities. centers for disease control and prevention

MalaCards based summary : Chronic Fatigue Syndrome, also known as myalgic encephalomyelitis, is related to personality disorder and ulcerative colitis, and has symptoms including back pain, fatigue and fever. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Dopamine and Sodium oxybate have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and prostate, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and behavior/neurological

NIH Rare Diseases : 50 chronic fatigue syndrome, also known as systemic exertion intolerance disease, is a condition that causes extreme, long-lasting fatigue which can limit the ability to participate in ordinary, daily activities. it generally occurs in young adults (20 to 40 years of age) and is twice as common in women. the main symptom is disabling fatigue that does not improve with rest. other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes. the exact cause is not known. there is still no cure or effective treatment for this condition but there are several clinical trials. there is controversy and debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome and there is no consensus on nomenclature or classification for these disorders. different countries, organizations, and researchers continue to use different names to describe these conditions. last updated: 10/18/2016

CDC : 3 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, long-term illness that affects many body systems. People with ME/CFS are often not able to do their usual activities. At times, ME/CFS may confine them to bed. People with ME/CFS have severe fatigue and sleep problems. ME/CFS may get worse after people with the illness try to do as much as they want or need to do. This symptom is known as post-exertional malaise (PEM). Other symptoms can include problems with thinking and concentrating, pain, and dizziness.

Disease Ontology : 12 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

Wikipedia : 72 Chronic fatigue syndrome (CFS), also referred to as myalgic encephalomyelitis (ME), is a medical... more...

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 325)
id Related Disease Score Top Affiliating Genes
1 personality disorder 29.7 COMT CRH HTR1A MAOA POMC SLC6A4
2 ulcerative colitis 29.3 COMT IGF1 IL10 IL6 TNF
3 rheumatoid arthritis 28.6 IL10 IL1B IL2 IL6 TGFB1 TNF
4 irritable bowel syndrome 11.0
5 chronic pain 11.0
6 chronic active epstein-barr virus infection 11.0
7 actinobacillosis 10.8 CRH NR3C1 POMC
8 balkan hemorrhagic fever 10.8 COMT IL10
9 prolactin producing pituitary tumor 10.8 IGF1 POMC
10 trabecular follicular adenocarcinoma 10.8 CRH NR3C1 POMC
11 bronchiectasis 10.8 CRH NR3C1 POMC
12 cold-induced sweating syndrome 2 10.8 CRH NR3C1 POMC
13 adrenal cortex disease 10.8 CRH NR3C1 POMC
14 monosomy 13q34 10.7 IL6 POMC
15 conjunctival pigmentation 10.7 CRH MAOA SLC6A4
16 ulcerative blepharitis 10.7 CRH IGF1 POMC
17 febrile infection-related epilepsy syndrome 10.7 CRH IGF1 POMC
18 traumatic glaucoma 10.7 CRH IGF1 POMC
19 myopia 25, autosomal dominant 10.7 IL10 IL2 NR3C1
20 cardiovascular organ benign neoplasm 10.7 CRH IGF1 POMC
21 tongue disease 10.7 COMT MAOA SLC6A4
22 corticosteroid-binding globulin deficiency 10.7
23 persian gulf syndrome 10.7
24 scirrhous adenocarcinoma 10.7 IL2 TNF
25 vestibular gland benign neoplasm 10.7 CRH IGF1 POMC
26 coloboma 10.7 CRH NR3C1 POMC
27 uterine ligament clear cell adenocarcinoma 10.7 CRH IGF1 POMC
28 anosognosia 10.7 COMT HTR1A SLC6A4
29 hallucinogen dependence 10.7 CRH POMC SLC6A4
30 capillary lymphangioma 10.6 CRH IGF1 POMC
31 perinatal necrotizing enterocolitis 10.6 COMT POMC SLC6A4
32 suppurative periapical periodontitis 10.6 IGF1 POMC SLC6A4
33 congenital nonspherocytic hemolytic anemia 10.6 IL1B IL6 POMC
34 pure autonomic failure 10.6 IL10 TNF
35 smarca4-deficient sarcoma of thorax 10.6 IL6 TNF
36 chondroma 10.6 IGF1 IL6 POMC
37 carotid stenosis 10.6 COMT MAOA SLC6A4
38 luxation of globe 10.6 HTR1A IL6 SLC6A4
39 oculomotor nerve paralysis 10.6 IL1B IL6
40 primary angle-closure glaucoma 10.6 COMT HTR1A SLC6A4
41 pervasive developmental disorder 10.6 COMT POMC SLC6A4
42 tinea pedis 10.6 HTR1A MAOA SLC6A4
43 acute ackee fruit intoxication 10.6 IL10 TNF
44 x-linked dominant intellectual disability-epilepsy syndrome 10.6 IL1B IL2 IL6
45 angiokeratoma of mibelli 10.6 HTR1A MAOA SLC6A4
46 chagas disease 10.6 COMT MAOA SLC6A4
47 colon mucinous adenocarcinoma 10.6 COMT MAOA SLC6A4
48 allergic asthma 10.6 CRH IGF1 POMC
49 myelitis 10.6 IL10 IL2 IL6
50 infancy electroclinical syndrome 10.6 IL10 IL1B IL6

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:



Diseases related to Chronic Fatigue Syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:


back pain, fatigue, fever, (non-specific) malaise and fatigue, muscle cramp, muscle rigidity, muscle spasticity, pruritus, sciatica, muscle weakness, myalgia, other malaise and fatigue

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 PDCD2 TGFB1 TNF EIF2AK2 IL10 IL1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 PDCD2 TGFB1 TNF EIF2AK2 IL10 IL1B
3 Decreased viability with paclitaxel GR00179-A-1 9.35 IGF1 IL10 TGFB1
4 Decreased viability with paclitaxel GR00179-A-2 9.35 IGF1
5 Decreased viability with paclitaxel GR00179-A-3 9.35 TGFB1

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 COMT CRH HTR1A IL10 IL2 IL6
2 cardiovascular system MP:0005385 10.41 TPH2 COMT HTR1A IGF1 IL10 IL1B
3 homeostasis/metabolism MP:0005376 10.41 SUN2 TGFB1 TNF TPH2 COMT CRH
4 growth/size/body region MP:0005378 10.35 PDCD2 POMC SLC6A4 SUN2 TGFB1 TNF
5 cellular MP:0005384 10.34 CRH EIF2AK2 IGF1 IL10 IL2 IL6
6 hematopoietic system MP:0005397 10.34 NR3C1 POMC RNASEL TGFB1 TNF COMT
7 endocrine/exocrine gland MP:0005379 10.33 COMT CRH IGF1 IL10 IL2 IL6
8 immune system MP:0005387 10.31 COMT CRH EIF2AK2 IGF1 IL10 IL1B
9 mortality/aging MP:0010768 10.31 TNF TPH2 EIF2AK2 HTR1A IGF1 IL10
10 integument MP:0010771 10.26 CRH IGF1 IL10 IL1B IL6 NR3C1
11 nervous system MP:0003631 10.22 TNF TPH2 TRPM3 COMT CRH HTR1A
12 adipose tissue MP:0005375 10.19 CRH IGF1 IL6 NR3C1 POMC TGFB1
13 liver/biliary system MP:0005370 10.06 CRH IL10 IL2 IL6 NR3C1 POMC
14 neoplasm MP:0002006 10.02 EIF2AK2 IGF1 IL10 IL1B IL2 IL6
15 muscle MP:0005369 10.01 IGF1 IL10 IL6 NR3C1 SLC6A4 SUN2
16 no phenotypic analysis MP:0003012 9.86 HTR1A IL10 IL2 NR3C1 POMC TNF
17 reproductive system MP:0005389 9.81 COMT IGF1 IL10 IL2 IL6 NR3C1
18 respiratory system MP:0005388 9.65 IL10 IL2 IL6 NR3C1 TGFB1 TNF
19 skeleton MP:0005390 9.28 IL6 NR3C1 PDCD2 TGFB1 TNF CRH

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
2
Sodium oxybate Approved Phase 4 502-85-2 5360545
3
Dinoprostone Approved Phase 4 363-24-6 5280360
4
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
5
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
6
Iron Approved Phase 4 7439-89-6 23925
7
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
8
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
9
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
10 tannic acid Approved, Nutraceutical Phase 4
11 Central Nervous System Depressants Phase 4,Phase 2,Phase 3
12 Adjuvants, Anesthesia Phase 4,Phase 1
13 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
14 Central Nervous System Stimulants Phase 4,Phase 2
15 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
17 Anesthetics Phase 4,Phase 1
18 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
19 Anesthetics, General Phase 4
20 Anesthetics, Intravenous Phase 4
21 Dopamine Agents Phase 4,Phase 2,Phase 3
22 Dopamine Uptake Inhibitors Phase 4,Phase 2
23 Ergocalciferols Phase 4
24 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
25 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
26 Bone Density Conservation Agents Phase 4
27 Sildenafil Citrate Phase 4 171599-83-0
28 Vasodilator Agents Phase 4,Phase 1
29 Anti-Bacterial Agents Phase 4,Phase 3
30 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
31 Phosphodiesterase 5 Inhibitors Phase 4
32 Phosphodiesterase Inhibitors Phase 4
33 Lisdexamfetamine Dimesylate Phase 4
34 Antibiotics, Antitubercular Phase 4,Phase 3
35 Antimalarials Phase 4
36 Liver Extracts Phase 4
37 Antiprotozoal Agents Phase 4
38 Antiparasitic Agents Phase 4
39 Ferric Compounds Phase 4
40 Hematinics Phase 4
41 Vitamin D2 Nutraceutical Phase 4
42 Calciferol Nutraceutical Phase 4
43 Citrate Nutraceutical Phase 4
44
Citric Acid Nutraceutical, Vet_approved Phase 4 77-92-9 311
45
Amitriptyline Approved Phase 2, Phase 3 50-48-6 2160
46
Perphenazine Approved Phase 2, Phase 3 58-39-9 4748
47
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
48
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
49
Melatonin Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 73-31-4 896
50
Vitamin C Approved, Nutraceutical Phase 2, Phase 3 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 118)

id Name Status NCT ID Phase Drugs
1 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
2 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
3 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
4 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
5 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome Completed NCT01071044 Phase 4 Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg"
6 Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS Completed NCT00598585 Phase 4 Sildenafil (Viagra);Placebo
7 Giardia Induced Fatigue and Functional Gastrointestinal Diseases Completed NCT00860236 Phase 4
8 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Completed NCT01318356 Phase 4 Doxycycline;Placebo
9 A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis. Recruiting NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
10 Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome Terminated NCT00498485 Phase 4 Placebo;Sodium Oxybate
11 Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS. Unknown status NCT01907711 Phase 2, Phase 3
12 Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise Unknown status NCT01689467 Phase 2, Phase 3
13 Immune-Pineal Axis Function in Fibromyalgia Unknown status NCT02041455 Phase 2, Phase 3 Melatonin and Placebo;Amitriptyline and Placebo;Melatonin and Amitriptylin
14 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
15 Drug Intervention in Chronic Fatigue Syndrome Completed NCT00848692 Phase 2, Phase 3 Rituximab;Saline (NaCl 0,9 %) (placebo)
16 The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Completed NCT00215800 Phase 3 Ampligen
17 Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Completed NCT00375973 Phase 2, Phase 3 Duloxetine;Placebo
18 Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients Completed NCT01742013 Phase 3 GCJBP Laennec Inj.;Placebo
19 Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. Completed NCT02063126 Phase 2, Phase 3
20 Exercise and Behavioral Therapy Trial (EBT). Completed NCT00007748 Phase 3
21 Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ Completed NCT00552682 Phase 3 Duloxetine 60 mg, QD
22 Study and Treatment of Post Lyme Disease (STOP-LD) Completed NCT00000937 Phase 3 Antibiotics
23 Probiotic (Visbiome) for Gulf War Illness Recruiting NCT03078530 Phase 2, Phase 3 Placebo;Visbiome
24 Ampligen in Chronic Fatigue Syndrome Active, not recruiting NCT00215813 Phase 3 Poly I: Poly C12U (Rintatolimod)
25 B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. Active, not recruiting NCT02229942 Phase 3 Rituximab;Placebo
26 Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue Terminated NCT00518869 Phase 2, Phase 3 PG2
27 Probiotic (Visbiome) for Gulf War Illness Terminated NCT02011542 Phase 2, Phase 3 Visbiome;Placebo
28 The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome Unknown status NCT01966276 Phase 2 Methyl-P plus Nutrient Formula;Methyl-P plus Nutrient matched placebos
29 Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®) Unknown status NCT01793415 Phase 1, Phase 2 IodoCarb (r)
30 Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) Unknown status NCT00478465 Phase 1, Phase 2 valganciclovir
31 Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Completed NCT00540254 Phase 1, Phase 2
32 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Completed NCT01156909 Phase 2 Rituximab
33 Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome Completed NCT01512342 Phase 2
34 The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial Completed NCT01040429 Phase 2 Clonidine;Lactose capsula
35 Acupressure for Post-Treatment Cancer Fatigue Completed NCT00959998 Phase 2
36 Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain Completed NCT00524420 Phase 2
37 Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI) Completed NCT00810368 Phase 2 Carnosine;Placebo
38 Creatine Supplementation in Chronic Fatigue Syndrome Active, not recruiting NCT02374112 Phase 2
39 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) Active, not recruiting NCT02444091 Phase 2 Cyclophosphamide
40 High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome Not yet recruiting NCT02924831 Phase 2
41 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome Terminated NCT01156922 Phase 2 Rituximab
42 Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Terminated NCT01730495 Phase 2 Etanercept
43 Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome Terminated NCT00977171 Phase 2 Droxidopa
44 Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder Withdrawn NCT01471652 Phase 2 Nutraceutical supplements;Placebo
45 Autonomic Nervous System and Chronic Fatigue Syndrome Completed NCT00580619 Phase 1 L-NMMA trimethaphan;methyldopa
46 Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Recruiting NCT02854683 Phase 1 Normal Saline
47 A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects Recruiting NCT02955420 Phase 1 BC 007;NaCl 0.9 %
48 Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder Withdrawn NCT01872351 Phase 1 Nutraceuticals
49 Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome Unknown status NCT01893619
50 Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome Unknown status NCT01534130

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

MalaCards organs/tissues related to Chronic Fatigue Syndrome:

39
Lymph Node, Testes, Prostate, Brain, B Cells, Pituitary, Amygdala

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 814)
id Title Authors Year
1
Distress signals: Does cognitive behavioural therapy reduce or increase distress in chronic fatigue syndrome/myalgic encephalomyelitis? ( 28805513 )
2017
2
Examining clinical similarities between myalgic encephalomyelitis/chronic fatigue syndrome and D-lactic acidosis: a systematic review. ( 28592308 )
2017
3
Altered right anterior insular connectivity and loss of associated functions in adolescent chronic fatigue syndrome. ( 28880891 )
2017
4
Gross and fine motor function in fibromyalgia and chronic fatigue syndrome. ( 28223840 )
2017
5
Cognitive remediation training improves performance in patients with chronic fatigue syndrome. ( 28830024 )
2017
6
Cognitive and behavioral coping in people with Chronic fatigue syndrome: An exploratory study searching for intervention targets for depressive symptoms. ( 28810458 )
2017
7
PACE trial claims for recovery in myalgic encephalomyelitis/chronic fatigue syndrome - true or false? It's time for an independent review of the methodology and results. ( 28805522 )
2017
8
Do graded activity therapies cause harm in chronic fatigue syndrome? ( 28805516 )
2017
9
FITNET's Internet-Based Cognitive Behavioural Therapy Is Ineffective and May Impede Natural Recovery in Adolescents with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. A Review. ( 28800089 )
2017
10
Chronic fatigue syndrome patients have no reason to accept the PACE trial results: Response to Keith J Petrie and John Weinman. ( 28805512 )
2017
11
Differential effects of childhood trauma subtypes on fatigue and physical functioning in chronic fatigue syndrome. ( 28806608 )
2017
12
Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome. ( 28129747 )
2017
13
Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. ( 27998507 )
2017
14
Treatment and management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: all roads lead to Rome. ( 28052319 )
2017
15
Depression, evening salivary cortisol and inflammation in chronic fatigue syndrome: A psychoneuroendocrinological structural regression model. ( 28918107 )
2017
16
Clinical and cost-effectiveness of the Lightning Process in addition to specialist medical care for paediatric chronic fatigue syndrome: randomised controlled trial. ( 28931531 )
2017
17
Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. ( 27727448 )
2017
18
Cognitive behaviour therapy and objective assessments in chronic fatigue syndrome. ( 28805529 )
2017
19
Symptoms of chronic fatigue syndrome/myalgic encephalopathy are not determined by activity pacing when measured by the chronic pain coping inventory. ( 28843450 )
2017
20
Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. ( 28059425 )
2017
21
Myalgic encephalomyelitis/chronic fatigue syndrome patients' reports of symptom changes following cognitive behavioural therapy, graded exercise therapy and pacing treatments: Analysis of a primary survey compared with secondary surveys. ( 28847166 )
2017
22
How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic fatigue syndrome studies? ( 28810428 )
2017
23
Impact of Rantes from jawbone on Chronic Fatigue Syndrome. ( 28685531 )
2017
24
Physiological measures in participants with chronic fatigue syndrome, multiple sclerosis and healthy controls following repeated exercise: a pilot study. ( 28782878 )
2017
25
What treatments work for anxiety in children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)? Systematic review. ( 28877941 )
2017
26
Cross-Cultural Study of Information Processing Biases in Chronic Fatigue Syndrome: Comparison of Dutch and UK Chronic Fatigue Patients. ( 28836119 )
2017
27
Bias, misleading information and lack of respect for alternative views have distorted perceptions of myalgic encephalomyelitis/chronic fatigue syndrome and its treatment. ( 28805527 )
2017
28
Children's experiences of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review and meta-ethnography of qualitative studies. ( 28087544 )
2017
29
Inflammation correlates with symptoms in chronic fatigue syndrome. ( 28811366 )
2017
30
Poor sleep quality is associated with greater circulating pro-inflammatory cytokines and severity and frequency of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) symptoms in women. ( 28038892 )
2017
31
Is the immune neuroendocrine system the connection between epipharyngitis and chronic fatigue syndrome induced by HPV vaccine? : Editorial. ( 27605126 )
2016
32
Metabolic mechanism of a polysaccharide from Schisandra chinensis to relieve chronic fatigue syndrome. ( 27545408 )
2016
33
Obesity in adolescents with chronic fatigue syndrome: an observational study. ( 27655658 )
2016
34
Stressful Events in the Onset of Chronic Fatigue Syndrome. ( 27535808 )
2016
35
Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study. ( 27123773 )
2016
36
Exercise therapy for chronic fatigue syndrome. ( 27995604 )
2016
37
Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome. ( 27125909 )
2016
38
Emotional conflict processing in adolescent chronic fatigue syndrome: A pilot study using functional magnetic resonance imaging. ( 27647312 )
2016
39
Genetic variation in catechol-O-methyltransferase modifies effects of clonidine treatment in chronic fatigue syndrome. ( 27457818 )
2016
40
Emotional Suppression in Chronic Fatigue Syndrome: Experimental Study. ( 27183308 )
2016
41
Cognitive behavioural therapy in the treatment of chronic fatigue syndrome: A narrative review on efficacy and informed consent. ( 27634687 )
2016
42
Fatigue Exacerbation by Interval or Continuous Exercise in Chronic Fatigue Syndrome. ( 27183124 )
2016
43
A UK based review of recommendations regarding the management of chronic fatigue syndrome. ( 27521650 )
2016
44
The Relationship between Age and Illness Duration in Chronic Fatigue Syndrome. ( 27110826 )
2016
45
Mortality in Patients with Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. ( 28070451 )
2016
46
Epistemic injustice in healthcare encounters: evidence from chronic fatigue syndrome. ( 27920164 )
2016
47
Correction: Therapist Effects and the Impact of Early Therapeutic Alliance on Symptomatic Outcome in Chronic Fatigue Syndrome. ( 27191956 )
2016
48
Cow's Milk Protein Intolerance in Adolescents and Young Adults with Chronic Fatigue Syndrome. ( 27177188 )
2016
49
Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. ( 28018972 )
2016
50
Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures. ( 27165859 )
2016

Variations for Chronic Fatigue Syndrome

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 EIF2AK2 IL10 IL1B IL2 IL6 MAOA
2
Show member pathways
13.32 IGF1 IL10 IL1B IL2 IL6 TGFB1
3
Show member pathways
12.93 IL10 IL1B IL2 IL6 TGFB1 TNF
4
Show member pathways
12.91 IL10 IL1B IL2 IL6 TGFB1 TNF
5
Show member pathways
12.85 EIF2AK2 IL1B IL2 IL6 RNASEL TNF
6
Show member pathways
12.75 EIF2AK2 IGF1 IL1B IL2 IL6 TGFB1
7
Show member pathways
12.65 IL10 IL1B IL2 IL6 TGFB1 TNF
8
Show member pathways
12.64 EIF2AK2 IL10 IL1B IL2 IL6 TNF
9 12.59 IL10 IL1B IL2 RNASEL TNF
10
Show member pathways
12.49 IL10 IL1B IL2 IL6 TGFB1 TNF
12 12.29 IL10 IL1B IL6 TGFB1 TNF
13
Show member pathways
12.28 IL10 IL1B TGFB1 TNF
14
Show member pathways
12.14 IGF1 IL10 IL6 TGFB1
15
Show member pathways
12.14 IL10 IL1B IL2 IL6 RNASEL TNF
16 12.12 IGF1 IL6 NR3C1 TGFB1 TNF
17 12.07 IL1B IL2 IL6 TGFB1 TNF
18 12.06 IL10 IL2 IL6 TNF
19 12.04 HTR1A MAOA SLC6A4 TPH2
20 11.99 IGF1 IL1B IL6 RNASEL TGFB1
21 11.97 IL1B IL6 TGFB1 TNF
22 11.94 CRH IL2 POMC TGFB1
23 11.92 IL1B IL6 TGFB1 TNF
24 11.9 IL10 IL1B IL6 TGFB1 TNF
25 11.87 IL2 IL6 NR3C1 POMC
26 11.86 IL10 IL1B IL2 TNF
27 11.83 IL10 IL1B IL6 TNF
28
Show member pathways
11.83 IL10 IL1B IL2 IL6 TGFB1 TNF
29 11.77 IL10 IL6 TGFB1 TNF
30 11.76 IL10 IL1B IL6 MAOA POMC TGFB1
31 11.69 IGF1 IL1B IL6 TGFB1 TNF
32
Show member pathways
11.67 IL1B IL2 IL6 NR3C1 TNF
33 11.62 IL1B IL6 TNF
34 11.61 IL10 IL1B IL6 TNF
35 11.61 IL10 IL1B IL2 IL6 TGFB1 TNF
36 11.59 IL2 IL6 TNF
37 11.59 IL1B IL2 TGFB1 TNF
38 11.56 IGF1 IL6 TGFB1
39 11.52 IL10 IL1B IL6 TGFB1 TNF
40 11.49 HTR1A IL10 IL1B IL6 MAOA NR3C1
41
Show member pathways
11.46 IL10 IL2 TGFB1 TNF
42 11.46 IGF1 IL1B IL6 NR3C1 TNF
43
Show member pathways
11.4 IL1B MAOA SLC6A4 TNF TPH2
44 11.39 IL10 IL1B IL6 TNF
45 11.38 IL10 IL1B IL6 TNF
46 11.37 IL1B IL6 TNF
47 11.35 IL1B IL6 TNF
48
Show member pathways
11.29 COMT MAOA SLC6A4
49 11.27 IL10 IL1B IL2 IL6 TNF
50 11.26 HTR1A MAOA SLC6A4 TPH2

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 CRH IGF1 IL10 IL1B IL2 IL6

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.99 CRH IL10 IL1B IL6 TGFB1 TNF
2 positive regulation of gene expression GO:0010628 9.97 CRH IL1B IL6 SLC6A4 TGFB1 TNF
3 response to lipopolysaccharide GO:0032496 9.96 COMT IL10 IL1B IL6
4 response to drug GO:0042493 9.91 COMT CRH IL10 IL6 SLC6A4 TGFB1
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.88 IL6 TGFB1 TNF
6 cellular response to organic cyclic compound GO:0071407 9.88 IL1B TGFB1 TNF
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 IGF1 IL2 IL6
8 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.86 IL10 IL1B IL6 TNF
9 positive regulation of epithelial cell proliferation GO:0050679 9.85 IGF1 IL6 TGFB1
10 positive regulation of T cell proliferation GO:0042102 9.85 IL1B IL2 IL6
11 positive regulation of cell proliferation GO:0008284 9.85 CRH HTR1A IGF1 IL2 IL6 TGFB1
12 positive regulation of cell migration GO:0030335 9.84 IGF1 SUN2 TGFB1
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 IGF1 IL6 TNF
14 response to organic substance GO:0010033 9.83 IL10 SLC6A4 TGFB1 TNF
15 negative regulation of fat cell differentiation GO:0045599 9.82 IL6 TGFB1 TNF
16 positive regulation of interleukin-6 production GO:0032755 9.81 IL1B IL6 TNF
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 IL1B IL6 TNF
18 positive regulation of protein phosphorylation GO:0001934 9.8 CRH IL1B IL2 TGFB1 TNF
19 positive regulation of interferon-gamma production GO:0032729 9.79 IL1B IL2 TNF
20 negative regulation of viral genome replication GO:0045071 9.79 EIF2AK2 RNASEL TNF
21 response to glucocorticoid GO:0051384 9.76 IL10 IL6 TNF TPH2
22 negative regulation of mitotic cell cycle GO:0045930 9.75 IL10 TGFB1 TNF
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.74 IL1B TGFB1 TNF
24 positive regulation of immunoglobulin secretion GO:0051024 9.71 IL2 IL6
25 positive regulation of protein import into nucleus, translocation GO:0033160 9.71 IGF1 IL6
26 neurotransmitter catabolic process GO:0042135 9.7 COMT MAOA
27 positive regulation of regulatory T cell differentiation GO:0045591 9.7 IL2 TGFB1
28 catecholamine metabolic process GO:0006584 9.69 COMT MAOA
29 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IL1B TNF
30 negative regulation of lipid storage GO:0010888 9.69 IL6 TNF
31 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
32 dopamine catabolic process GO:0042420 9.67 COMT MAOA
33 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
34 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
35 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.65 IL6 TNF
36 positive regulation of chemokine production GO:0032722 9.65 EIF2AK2 IL6 TNF
37 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.65 EIF2AK2 IL1B IL6 TGFB1 TNF
38 positive regulation of fever generation GO:0031622 9.63 IL1B TNF
39 sequestering of triglyceride GO:0030730 9.61 IL1B TNF
40 positive regulation of mononuclear cell migration GO:0071677 9.6 TGFB1 TNF
41 receptor biosynthetic process GO:0032800 9.59 IL10 TNF
42 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IL1B TNF
43 regulation of hematopoietic progenitor cell differentiation GO:1901532 9.55 EIF2AK2 PDCD2
44 regulation of serotonin secretion GO:0014062 9.54 CRH HTR1A
45 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.5 IL10 IL1B TNF
46 cellular response to dexamethasone stimulus GO:0071549 9.46 CRH IL6 NR3C1 TGFB1
47 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.32 IGF1 IL10 IL1B IL2 IL6 NR3C1
48 protein kinase B signaling GO:0043491 9.26 IGF1 IL1B TGFB1 TNF
49 immune response GO:0006955 10.1 IL10 IL1B IL2 IL6 TNF
50 positive regulation of transcription, DNA-templated GO:0045893 10.1 IGF1 IL10 IL1B IL6 TGFB1 TNF

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IGF1 IL10 IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.1 IL10 IL1B IL2 IL6 TGFB1 TNF

Sources for Chronic Fatigue Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....